GemPharmatech Co Ltd
SSE:688046
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
GemPharmatech Co Ltd
Operating Income
GemPharmatech Co Ltd
Operating Income Peer Comparison
603259
300759
2269
300347
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
G
|
GemPharmatech Co Ltd
SSE:688046
|
Operating Income
¥155.4m
|
CAGR 3-Years
22%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
WuXi AppTec Co Ltd
SSE:603259
|
Operating Income
¥10.9B
|
CAGR 3-Years
43%
|
CAGR 5-Years
40%
|
CAGR 10-Years
N/A
|
|
|
Pharmaron Beijing Co Ltd
SZSE:300759
|
Operating Income
¥1.7B
|
CAGR 3-Years
11%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
Operating Income
¥4.1B
|
CAGR 3-Years
36%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
Operating Income
¥1.6B
|
CAGR 3-Years
19%
|
CAGR 5-Years
25%
|
CAGR 10-Years
32%
|
|
M
|
MGI Tech Co Ltd
SSE:688114
|
Operating Income
¥190.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is GemPharmatech Co Ltd's Operating Income?
Operating Income
155.4m
CNY
Based on the financial report for Dec 31, 2023, GemPharmatech Co Ltd's Operating Income amounts to 155.4m CNY.
What is GemPharmatech Co Ltd's Operating Income growth rate?
Operating Income CAGR 3Y
22%
Over the last year, the Operating Income growth was -4%. The average annual Operating Income growth rates for GemPharmatech Co Ltd have been 22% over the past three years .
You don't have any saved screeners yet
